Physician profile
Vanessa Murad
NPI 1154879989
$4,906.07
in general payments reported to CMS, 2019-2025
24 companies · $941 in 2025
The $941 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,341 · 2022: $983 · 2023: $1,123 · 2024: $518 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,582.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,953.44 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $660.56 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $302.02 | 2021-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.22 | 2021-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $247.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $161.63 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $157.55 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $156.52 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $125.41 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $122.03 | 2021 | |
| Madrigal Pharmaceuticals | $117.51 | 2024-2025 | Rezdiffra |
| Celgene Corporation | $104.01 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $100.30 | 2021-2023 | Dificid |
| Daiichi Sankyo INC. | $75.46 | 2021-2023 | Injectafer |
| Qol Medical, LLC | $73.07 | 2021-2023 | Sucraid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $73.03 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $59.16 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $32.43 | 2023 | |
| Organon LLC | $22.90 | 2021 | |
| Redhill Biopharma INC. | $20.63 | 2022 | |
| Boston Scientific Corporation | $19.40 | 2025 | General - Pain Management |
| Phathom Pharmaceuticals, INC. | $19.26 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $17.96 | 2025 | Zenpep |
| Novo Nordisk INC | $17.42 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Murad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.